Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence

被引:58
作者
Alexander-Sefre, F
Chandrakumaran, K
Banerjee, S
Sexton, R
Thomas, JM
Cecil, T
Moran, B
机构
[1] N Hampshire Hosp, Pseudomyxoma Peritonei Ctr, Basingstoke RG24 9NA, Hants, England
[2] Canc Res UK, Translat Oncol Lab, London, England
[3] St Bartholomews & Royal London Med & Dent Sch, Dept Informat Serv, London, England
关键词
pseudomyxoma peritonei; pre-operative tumour; markers; cytoreduction; recurrence; carcinoembryonic antigen;
D O I
10.1111/j.1463-1318.2005.00773.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To assess the potential value of pre-operative CEA, CA 125 and CA 19-9 in identifying Pseudornyxoma peritonei (PMP) patients at risk of recurrence following complete cytoreductive surgery and intraperitoneal chemotherapy. Method: Between March 1996 and October 2001, 35 patients, with documented pre-operative tumour marker measurements, underwent complete cytoreduction. Outcome in the 32 survivors was recorded. Results: Median age was 53 years (range: 32-74). There were 17[53%] females. In 9/32[28%] all turnout markers were normal. The most common abnormality was elevated CEA level in 14/32[44%]. Median follow up was 23 months (range: 11-74). Recurrence was detected in 8/32[25%]. The 2-year recurrence free interval was 53% in those with elevated CEA compared with 94% with normal CEA. The 2-year disease free intervals were 100% in 9 patients with normal preop markers compared with 66% for the group with at least one abnormal marker. Conclusion: PMP patients with elevated CEA, or more than one abnormal serum turnout maker, are at risk of developing recurrent disease.
引用
收藏
页码:382 / 386
页数:5
相关论文
共 31 条
[1]
BEATTY JD, 1979, ARCH SURG-CHICAGO, V114, P563
[2]
Reference levels of the tumor markers carcinoembryonic antigen, the carbohydrate antigens 19-9 and 72-4, and cytokeratin fragment 19 using the ®Elecsys Relecsys 1010 analyzer in a normal population in Kuwait.: The importance of the determination of local reference levels [J].
Behbehani, AI ;
Mathew, A ;
Farghaly, M ;
van Dalen, A .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (01) :67-70
[3]
Carpelan-Holmström M, 2002, ANTICANCER RES, V22, P2311
[4]
Gattani AM, 1996, CANCER, V78, P57, DOI 10.1002/(SICI)1097-0142(19960701)78:1<57::AID-CNCR10>3.0.CO
[5]
2-6
[6]
Gebauer G, 1997, ANTICANCER RES, V17, P2939
[7]
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study [J].
Glehen, O ;
Mithieux, F ;
Osinsky, D ;
Beaujard, AC ;
Freyer, G ;
Guertsch, P ;
Francois, Y ;
Peyrat, P ;
Panteix, G ;
Vignal, J ;
Gilly, FN .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :799-806
[8]
PSEUDOMYXOMA PERITONEI - LONG-TERM PATIENT SURVIVAL WITH AN AGGRESSIVE REGIONAL APPROACH [J].
GOUGH, DB ;
DONOHUE, JH ;
SCHUTT, AJ ;
GONCHOROFF, N ;
GOELLNER, JR ;
WILSON, TO ;
NAESSENS, JM ;
OBRIEN, PC ;
VANHEERDEN, JA .
ANNALS OF SURGERY, 1994, 219 (02) :112-119
[9]
Ikeda W, 2001, CANCER-AM CANCER SOC, V91, P490, DOI 10.1002/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO
[10]
2-L